paricalcitol / Generic mfg. - LARVOL DELTA

A phase II clinical trial of albumin-bound paclitaxel, cisplatin, gemcitabine (NABPLAGEM) and paricalcitol as neoadjuvant therapy in pancreatic cancer. (PubMed, Oncologist) - P2 | "Neoadjuvant NABPLAGEM plus paricalcitol demonstrated a high CA 19-9 normalization rate and was fairly well tolerated."

Journal • P2 data • Hematological Disorders • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • Thrombocytopenia

Gemcitabine and nab-paclitaxel with or without the VDR agonist paricalcitol for metastatic pancreatic cancer: a randomized, multiarm, run-in phase trial. (PubMed, Nat Cancer) - P1 | "Paricalcitol can be safely administered with chemotherapy to patients with metastatic pancreatic cancer, and on-treatment biopsies indicated favorable modulation of the tumor microenvironment by paricalcitol as predicted by preclinical models. ClinicalTrials.gov identifier: NCT03520790 ."

Journal • Endocrine Disorders • Metabolic Disorders • Oncology • Pancreatic Cancer • Solid Tumor • CD8 • VDR

Paricalcitol Attenuates Bleomycin-induced Pulmonary Fibrosis: Insights from Immunohistochemical and Molecular Genetic Analysis. (PubMed, Endocr Metab Immune Disord Drug Targets) - "Paricalcitol markedly reduces fibrosis severity, as shown through histopathological, immunohistochemical, and molecular genetic analyses. The treatment decreased the expression of key fibrotic and inflammatory markers, including TGF-β, MMP9, IL-1β, and TNF-α, and shifted macrophage polarization toward an anti-inflammatory M2 phenotype. These findings suggest paricalcitol's potential in modulating the immune response and highlight its therapeutic promise."

Journal • Fibrosis • Immunology • Inflammation • Pulmonary Disease • Respiratory Diseases • CD163 • CD80 • IL1B • MMP9 • TGFB1 • TNFA

Efficacy and Safety of Paricalcitol Therapy for Kidney Transplantation Recipients: A Systematic Review and Meta-analysis of Randomized Controlled Trials. (PubMed, Transplant Proc) - "Paricalcitol lowers short-term parathyroid hormone but increases serum calcium and hypercalcemia risk. Evidence for proteinuria, rejection, graft survival, and patient outcomes remains insufficient because the trials were few, heterogeneous, and short."

Journal • Retrospective data • Endocrine Disorders • Metabolic Disorders • Transplantation

Vitamin D Pathway Activation Reduces Cardiomyocyte DNA Damage and Improves Cardiac Contractility in Preclinical Models. (PubMed, JACC Adv) - "Vitamin D pathway activation improved contractile phenotypes across complementary preclinical models and was accompanied by reduced γH2AX foci or related transcriptional changes. These findings support further mechanistic and preclinical investigation."

Journal • Preclinical • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • LMNA

Cost-effectiveness analysis comparison of etelcalcetide, paricalcitol, and cinacalcet for the treatment of secondary hyperparathyroidism in patients with chronic kidney disease. (PubMed, Expert Rev Pharmacoecon Outcomes Res) - "The optimal pharmacological strategy for SHPT depends on the WTP threshold. Cinacalcet is preferred at lower WTP levels, while etelcalcetide offers superior cost-effectiveness at higher WTP."

HEOR • Journal • Cardiovascular • Chronic Kidney Disease • Endocrine Disorders • Musculoskeletal Diseases • Nephrology • Orthopedics • Renal Disease • Secondary Hyperparathyroidism

Co-Clinical Evaluation of Synthetic Vitamin D and Chemotherapy in Pancreatic Cancer by Integrated Imaging and Molecular Analyses. (PubMed, Cancer Res Commun) - P1 | "These findings support further investigations of stromal-directed combination strategies to overcome chemotherapy-induced resistance of PDAC. DCE-MRI may provide a valuable platform to monitor stromal adaptations to therapy in vivo."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • TGFB1

ALLIANCE: A PiLot ClinicaL TrIal of ParicAlcitol for ChroNiC PancrEatitis (clinicaltrials.gov) - P1 | N=24 | Active, not recruiting | Sponsor: Cedars-Sinai Medical Center | Recruiting ➔ Active, not recruiting | Trial completion date: Dec 2026 ➔ Dec 2027 | Trial primary completion date: Jun 2026 ➔ Jul 2027

Enrollment closed • Trial completion date • Trial primary completion date • Pancreatitis

Intravenous Paricalcitol Versus Calcitriol for Secondary Hyperparathyroidism in Maintenance Hemodialysis: A Six-Month Single-Center Retrospective Cohort Study. (PubMed, J Clin Med) - " Intravenous paricalcitol was not associated with superior 6-month PTH control compared with intravenous calcitriol in this real-world maintenance hemodialysis cohort. The findings indicate no demonstrated superiority of paricalcitol in this cohort and should not be interpreted as proof of pharmacological equivalence."

Journal • Retrospective data • Chronic Kidney Disease • Endocrine Disorders • Metabolic Disorders • Nephrology • Orthopedics • Renal Disease • Secondary Hyperparathyroidism

Serum 25(OH) vitamin D and SIRT1- VDR- miR-124 expression: A controlled interventional study in a vitamin D-deficient male rat model. (PubMed, Exp Gerontol) - "A putative epigenetic relation was found between miR-124 levels and their association with SIRT1. The investigated biomarkers of aging are associated with serum concentration of 25(OH) vitamin D in a middle-aged vitamin D-deficient rat model, which supports the need for mechanistic investigation in future studies."

Journal • Preclinical • Oncology • SIRT1 • VDR

COL1A1 and SERPINE1 as Potential Therapeutic Targets in Diabetic Retinopathy: A Study Incorporating RNA Transcriptomics, Single-Cell RNA Sequencing, and Proteomics. (PubMed, Hum Mutat) - "Single-cell and molecular docking analyses revealed high expression of the two key genes in fibroblasts and binding between SERPINE1 and paricalcitol, and HG induction increased their levels in RMECs, whereas knockdown of SERPINE1 repressed RMEC proliferation, migration, and invasion in vitro. This study identifies SERPINE1 and COL1A1 as possible DR therapeutic targets, providing new insights into relevant therapeutic development."

Journal • Diabetes • Diabetic Retinopathy • Inflammation • Retinal Disorders • COL1A1 • SERPINE1 • TGFB1

Recurrent Calciphylaxis With Discordant Parathyroid Hormone Trajectory in a Patient With HIV-Associated End-Stage Renal Disease: A Case Report. (PubMed, Cureus) - "At initial presentation (T1), intact parathyroid hormone (iPTH) was 806.5 pg/mL; she was treated with paricalcitol, sevelamer carbonate, and intravenous sodium thiosulfate (STS) but remained intermittently nonadherent to hemodialysis and prescribed therapies, with a single-pool Kt/V of 0.29 documented at recurrence. Parathyroidectomy was deferred at T2 and T3 because of acute infectious burden and uncontrolled hyperkalemia, respectively. This case illustrates the diagnostic and management complexity of recurrent calciphylaxis in HIV-associated ESRD, demonstrates how intermittent treatment adherence may produce highly discordant iPTH measurements that complicate threshold-based monitoring, and underscores the importance of multidisciplinary planning before surgical and metabolic barriers to parathyroidectomy accumulate."

Journal • Calciphylaxis • Cardiovascular • Chronic Kidney Disease • Endocrine Disorders • Human Immunodeficiency Virus • Hypertension • Infectious Disease • Metabolic Disorders • Nephrology • Rare Diseases • Renal Disease • CD4

Secondary Prevention of Diabetes Type 1 with Oral Paricalcitol: The PRECAL Study (ENDO 2026) - "10 presented hypercalciuria/hypercalcemia, 1 nephrocalcinosis, resolving with dose titration/discontinuation. Calcitriol, and paricalcitol were effective and reasonably safe in negativizing T1Abs in healthy children, possibly preventing the otherwise probably inevitable evolution towards clinical development of T1D, at least if started soon enough after seroconversion."

Diabetes • Endocrine Disorders • Metabolic Disorders • Nephrology • Type 1 Diabetes Mellitus

THERAPEUTIC POTENTIAL OF VITAMIN D TREATMENTS ON MUCIN SECRETION IN CHEMOTHERAPY-INDUCED GASTROINTESTINAL MUCOSITIS (MASCC-ISOO 2026) - "All vitamin D treatments (calcitriol, paricalcitol, and VD1-6 ) significantly reduced (all p<0.0001) the number and proportion of cavitated goblet cells in 5-FU–treated mice compared with the 5-FU control group. Conclusions Vitamin D–based treatments attenuated 5-FU–induced goblet cell cavitation, suggesting partial preservation of goblet cell integrity and mucosal barrier function, supporting further investigation of secretory regulation pathways in goblet cells and vitamin D signalling pathways during chemotherapy-induced mucositis to promote protective function."

Mucositis • CYP24A1

Combination of paricalcitol with chemotherapy shows promise in phase 1 study of metastatic pancreatic cancer. (PubMed, Nat Cancer) - No abstract available

Journal • P1 data • Oncology • Pancreatic Cancer • Solid Tumor

Stage-dependent association of Vitamin D receptor with macrophage polarization in allergic rhinitis. (PubMed, Biochim Biophys Acta Gen Subj) - "VDR signaling is associated with stage-dependent immunomodulation in AR, promoting M2-like molecules expression during sensitization and suppressing M1 like driven inflammation during re-challenge, thereby weakening effects in the chronic phase. These findings support a "chronotherapeutic" application of VitD in AR."

Journal • Allergic Rhinitis • Immunology • Inflammation • ARG1 • CCL2 • CD163 • CXCL9 • IL1B • IL6 • MERTK • NOS2 • TNFA • VDR

Identification of drug-related cardiovascular risks: A comprehensive analysis using the FAERS database (2004-2024). (PubMed, PLoS One) - "This study showed that some drugs were significantly associated with CVD, and some of them were newly discovered signals. These findings provide a basis for the generation of new hypotheses about the cardiovascular risk of drugs, but the causal relationship needs to be confirmed by further research."

Journal • Retrospective data • Cardiovascular • Oncology

PHL Treatment in Pancreatic Cancer (clinicaltrials.gov) - P1 | N=20 | Active, not recruiting | Sponsor: Fox Chase Cancer Center | Recruiting ➔ Active, not recruiting | Trial primary completion date: Mar 2026 ➔ Dec 2025

Enrollment closed • Trial primary completion date • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

Paclitaxel Protein Bound Plus Cisplatin Plus Gemcitabine and Paricalcitol for Pancreatic Adenocarcinoma (NABPLAGEMD) (clinicaltrials.gov) - P2 | N=34 | Completed | Sponsor: HonorHealth Research Institute | N=11 ➔ 34

Enrollment change • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • Solid Tumor • CA 19-9

Pre-operative Treatment for Patients With Untreated Pancreatic Cancer (clinicaltrials.gov) - P2 | N=40 | Completed | Sponsor: HonorHealth Research Institute | Active, not recruiting ➔ Completed | N=24 ➔ 40 | Trial completion date: Aug 2025 ➔ Nov 2025

Enrollment change • Trial completion • Trial completion date • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor

Targeted therapeutics for pancreatitis. (PubMed, Front Physiol) - "Potential early interventions include Orai1 inhibition (CM4620/Auxora with early-phase human safety data and phase 2b signals), mitochondrial pore inhibition (NIM811) and other mitochondrial protectants...The emerging clinical pipeline includes repurposed anti-fibrotic or immunomodulatory agents (pirfenidone, paricalcitol, tocilizumab, proglumide), genotype-matched therapy (CFTR modulation in selected populations), and cell-based approaches...Therefore, progress will depend on matching treatment timing to target biology, identifying patients using practical early severity and inflammatory features, and using endpoints that reflect disease modification (organ failure, necrosis, recurrence, fibrosis progression, pancreatic function, and pain trajectories). Trial designs matching these therapeutics to their target biology will help understand the real clinical value of mechanism-based regimens across the AP-RAP-CP continuum."

Journal • Review • Fibrosis • Immunology • Inflammation • Pain • Pancreatitis • ADAM17 • HMGB1 • NLRP3

Synthetic Modulators of the Vitamin D Receptor: From Structural Innovation to Disease-Specific Applications. (PubMed, Biomolecules) - "We highlight medicinal chemistry strategies spanning secosteroidal analogs with side-chain or ring modifications and emerging non-seco scaffolds and discuss clinically established agents (e.g., calcipotriol and paricalcitol) alongside experimental "super-agonists", partial agonists, and antagonists designed to widen the therapeutic window. Finally, we discuss current evidence for VDR targeting across cancer, metabolic disease, fibrosis, and immune-inflammatory disorders, including mechanisms of resistance such as dysregulated vitamin D metabolism and epigenetic repression. Structural and epigenomic insights are positioning next-generation VDR ligands as tissue- and pathway-biased therapeutics that may enable safer, mechanism-guided translation beyond bone and mineral indications."

Journal • Review • Endocrine Disorders • Fibrosis • Immunology • Metabolic Disorders • Oncology

Integrated transcriptomics and proteomics analysis reveal potential target in pediatric primary restrictive cardiomyopathy. (PubMed, Pediatr Res) - "This study offers a novel perspective on the mechanisms underlying pediatric primary restrictive cardiomyopathy, specifically highlighting abnormalities in muscle regulation and the myocardial extracellular matrix. Additionally, the predicted therapeutic targets for pediatric primary restrictive cardiomyopathy indicate the new directions for their clinical management except for the treatment of advanced heart failure."

Journal • Cardiomyopathy • Cardiovascular • Congestive Heart Failure • Heart Failure • Pediatrics • CKB • TPM2

ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment. (PubMed, bioRxiv) - P1 | "We have previously shown that the combination of GPH (gemcitabine, paricalcitol, and hydroxychloroquine) influences PDAC TME. Targeting integrin αvβ3 using ProAgio modulates the PDAC TME by improving perfusion, reducing hypoxia, reversing EMT, and alleviating immune suppression. ProAgio potentiates the effects of GPH therapy, which should be evaluated in future trials."

Journal • Oncology • Pancreatic Cancer • Pancreatic Ductal Adenocarcinoma • CAFs • CD4

A Single-Center, Single-Arm, Open-Label Phase II Clinical Study of Recombination with Paricalcitol After First-Line PD-1 Inhibitor Regimen Failure in Unresectable Hepatocellular Carcinoma Patients with Serum Vitamin D Deficiency (ChiCTR) - P2 | N=53 | Not yet recruiting | Sponsor: The Third Affiliated Hospital of Naval Medical University; The Third Affiliated Hospital of Naval Medical University

New P2 trial • Hepatocellular Cancer • Oncology • Solid Tumor